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Abstract
OBJECTIVE: To evaluate clinical efficacy of point
application or adjuvant therapy on chronic obstruc-
tive pulmonary disease in stationary phase and ef-
fects on pulmonary functions.
METHODS: Computer retrieved CNKI, VIP, CBM and
other databanks and manual operations retrieved
correlative literatures to find randomized con-
trolled trials (RCTs) about comparison between
point application or adjuvant therapy and
no-point-applications for treatment of chronic ob-
structive pulmonary disease in stationary phase in
China. RevMan 5.0 software was used for Meta anal-
ysis.
RESULTS: Among 3481 cases in the inclusive 32
RCTS, 1780 cases were in the test group and 1701
cases in the control group. Meta analysis indicated:
1) clinical efficacy: the groups containing point ap-
plication therapy all were better than the groups of
no-point-application; 2) force vital capacity (FVC):
There was no statistically significant difference be-
tween the group of point application plus Western
Medicine and the Western Medicine group; 3) force
expiratory volume 1 (FEV1): The groups containing
point application therapy were better than the
no-point-application; 4) FEV1% : the groups of
point application plus Western Medicine were bet-
ter than the Western Medicine groups; 5) FEV1/FVC:
there was a significant difference between the
group of point application plus Chinese drugs and
the group of Chinese drug.
CONCLUSION: Point application can increase clini-
cal efficacy of chronic obstructive pulmonary dis-
ease in stationary phase in varying degrees, and dif-
ferent combinations of point application with Chi-
nese drugs or Western Medicines have incomplete
same actions in improvement of pulmonary func-
tion and therapeutic effect.
© 2012 JTCM. All rights reserved.
Key words: Pulmonary disease; Chronic obstruc-
tive; Traditional Chinese medicine; Acupoint stick-
ing therapy; Meta-analysis; Systematic evaluation
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a
disease characterized by limitation of gas flow and is
able to be prevented and treated, and the limitation of
gas flow is in-complete reversible with progressive de-
velopment. It is the forth lethal disease in the world at
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present. Epidemiological survey of COPD of Zhong
Nan-san and others in 7 provinces and cities between
2002-2004 indicated that the total sick rate of COPD
in the population of over 40 years old was 8.2%,1 be-
ing a very horrifying sick rate with a more heavy social
burden. Modern medicine has superiorities in alleviat-
ing symptoms at the acute stage and other aspects, but
there are insufficiencies in prevention at early stage,
preventing recurrence at stationary phase and rehabili-
tation treatment at the late state, being difficult to
meet medical need of the patient. However, applica-
tion therapy in Traditional Chinese Medicine (TCM)
has unique superiorities in these aspects. The patent ad-
hesive plaster or self-made drugs used in the respiration
department are prepared basically referring to the meth-
ods in Zhangshi Yitong, and modified in varying re-
gions according to different constitutions, diseases or
climatic characteristics. At present, application therapy
of TCM is widely applied for treatment of COPD at
the stationary phase in TCM and integrated TCM and
Western Medicine fields at home and abroad with tra-
ditional experience most carried on. However, it needs
to be further studied that whether or not the applica-
tion therapy or adjuvant therapy can increase the clini-
cal therapeutic effect and effects of this therapy on pul-
monary function in COPD patients, so as to provide
objective basis for clinical treatment.
METHODS
Criteria of inclusion and exclusion
Types of research: Randomized controlled trials in Chi-
na about TCM application or adjuvant therapies com-
pared with no-application therapy for treatment of
COPD at stationary phase in China.
Subjects of research: Clinically randomized controlled
trials of researches and publishing in China, and crite-
ria of diagnosis for COPD in stationary phase con-
formed with the Guidance of Diagnosis and Treatment
for Chronic Obstructive Pulmonary Diseases (draft) in
1997,2 edition 2002,3 revised edition 2007,4 or "2006
edition of "Global propose of chronic obstructive pul-
monary disease"5 stipulated by the Group of Chronic
Obstructive Pulmonary Diseases, the Branch of Respi-
ratory Diseases, Chinese Medical Association. The pa-
tients at stage of attack were excluded.
Measures of interfere: Application therapy or adju-
vant therapy, and the no-application therapy were
used respectively for treatment of COPD in the sta-
tionary phase in the test groups and in the control
group.
Indexes of final results: 1) clinical therapeutic effect; 2)
force vital capacity (FVC); 3) FVC%; 4) force expirato-
ry volume 1 (FEV1); 5) FEV1% ; 6) FEV1/FVC; 7)
the St. George's Hospital Respiratory Questionnaire;
8) cumulative score of TCM symptoms (Clinical symp-
toms); 9) quality of life (QOL); 10) times of acute attack;
11) 6-minute walk test (6MWT); 12) peak expiratory
flow (PEF); 13) BODE index(B-body mass index, O-ob-
structive degree of air flow; D-dyspnea; E-motor ability);
14) tumor necrosis factor-α (TNF-α); 15) maximum
ventilatory volume/min (MVV); 16) residual volume
(RV); 17) inspiratory capacity (IC); 18) vital capacity
(VC); 19) partial pressure of oxygen (PaO2), partial pres-
sure of carbon dioxide (PaCO2); 20) immunoglobulin G
(IgG), IgM, IgA; 21)CD4/CD8; 22)CD3,CD4,CD8.
Tactics of retrieval: With "mounting", "application"
used as retrieval words to retrieve CNKI, VIP, CBM da-
tabank, and the retrieval period was from the time of
the databank building to October 2011, and found out
the references of the inclusive literatures.
Extraction of data and evaluation of literature
quality
Two persons independently selected the tests and took
data and made quality evaluation, and checked cross-
ly to ensure identity of the results. If there was any
difference, discussion would be made for its resource,
and if it was necessary, the third researcher would be
inquired about. According to Cochrane Reviewer's
Handbook 5.0 the RCT quality was evaluated:
Whether or not random assignation was made cor-
rectly; whether or not there was assignation hiding
program; whether or not blind method was used;
whether or not there were description of lost follow-
ing-up, dropping off, if there was lost following-up
or dropping off, whether or not intention (ITT) anal-
ysis was made. If the above 4 items were met, it
would be evaluated as grade A, If one or more than
one items were unclear, it would be evaluated as
grade B, If one or over one items were incorrect, it
would be evaluated as grade C.
Statistical analysis
Review Manager 5.0 software was adopted for Meta
analysis. For two classification variables, OR and its
95%CI were used, for continuous variables, mean dif-
ference (MD) and its 95% CI were used. Chi-square
test was used for analysis of statistical heterogeneity
among the studies, For the study with good homogene-
ity (P>0.05, I2<50%), fixed efficacy model was used for
Meta analysis;If there was heterogeneity, firstly the re-
source of the heterogeneity was analyzed. If there was
no significant clinical heterogeneity among the studies,
the random efficacy model can be used for combina-
tive analysis and the results should be carefully ex-
plained. If the inclusive data could not be made Meta
analysis, only descriptive analysis would be used. When
number of the inclusive studies was enough, funnel
plot analysis could be used to investigate whether or
not there was publishing deviation.
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RESULTS
Results of literature retrieval
Eighty-eight relative papers were obtained in the first
screening, after reading the titles and the abstracts, and
the reviews, evaluation, case reports and abstracts of
conference were excluded, 61 papers were included.
After further reading the full text, finally, 32 papers of
randomized controlled trails were included 6-37 (Figure
1). Among them, in 16 papers, the therapeutic effect
of Western Medicine plus application was compared
with Western Medicine; 6-20,37 in 2 papers, Chinese drug
plus application was compared with Western Medi-
cine;21,22 in 3 papers, Chinese drugs plus application
was compared Chinese drugs;23-25 in one paper, Chinese
drug was compared with application;26 in 4 papers, ap-
plication was compared with Western Medicine;27-30 in
2 papers, Western Medicines plus Chinese drug was
compared with Western Medicine;31,32 in one paper ,
Western Medicine plus application plus point-injection
was compared with Western Medicine;33 in one paper,
Chinese patent medicine or Western Medicine was
compared with application;34 in 2 papers, application
was compared with blank control.35,36
In total, 3481 cases were included. Among them, 1780
cases were in the test group and 1701 were in the con-
trol group. The basic characteristics of inclusive re-
searches were showed in Table 1.
Quality assessment of inclusive researches
Evaluations of methodological quality of inclusive re-
searches are showed in Table 2. Among them, 4 re-
searches17,19,24,25 used random number table method, one
research22 used stratified block random method, and al-
location hiding program of all the researches were un-
clear, only one research22 used double blind, all the re-
searches did not mention use of Intention analysis, so
the quality was not high, being regarded as grade B,
and 5 researches7,13,21,22,31 mentioned occurrence of ad-
verse reactions in the patient after mounting.
Evaluation of clinical therapeutic effects
Clinical effective rate was used as evaluation of clinical
therapeutic effects, clinical effective rate=(clinical con-
trol number + remarked effect number + effective num-
ber) / (clinical control number+marked effect number+
effective number + ineffective number) × 100% . 18 re-
search reports of 4 subgroups reported clinically effec-
tive rates, among the tests there was no heterogeneity,
the mounting plus Western Medicine group compared
with the Western Medicine group (I2=3% , P=0.42),
the mounting plus Chinese drug group compared with
the Chinese drug group (I2=0%, P=0.38), the mount-
ing group compared with the Western Medicine group
(I2=0%, P=0.80), the mounting plus Chinese drug plus
Western Medicine group compared with the Western
Medicine group (I2=0%, P=0.45), so fixed effect model
was used for Meta analysis.The results showed that
when the 4 subgroups were compared, there were statis-
tical significances between the mounting plus Western
Medicine group and the Western Medicine group
[MD=4.00, 95% CI (2.93, 5.46), P<0.00001], the
mounting plus Chinese drug group and Chinese drug
group [MD=2.05, 95%CI (0.92, 4.99), P=0.089], the
mounting group and the Western Medicine group
[MD=3.52, 95% CI (1.95, 6.37), P<0.0001], the
mounting plus Chinese drug plus Western Medicine
group and the Western Medicine group [MD=3.19,
95%CI (1.49, 6.82), P=0.003], and there were statisti-
cal significances as all the mounting groups compared
with the un-mounting groups [MD=3.63, 95% CI
(2.84, 4.65), P<0.00001](Figure 2).
Evaluation of pulmonary functions
In this evaluation, the indexes FVC, FEV1, FEV1% ,
FEV1/FVC were included in evaluation of the pulmo-
nary function. For inclusive FVC evaluation, only
Consulted 88 papers
3 papers of repeated issue and 3
at acute stage were deleted
21 papers were deleted after read-
ing titles and abstracts
18 papers of cases series repots
deleted
5 papers about academic re-
search and 4 mechanisms deleted
2 papers about different applica-
tion comparison methods deleted
Surplus 82 papers
Surplus 61papers
Surplus 43papers
Surplus 34 papers
Inclusive 32 papers
Figure 1 Flow diagram of literature screening
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there were 4 researches6,7,17,19 in which the mounting
plus Western Medicine group was compared with the
Western Medicine group; There were 8 researches for
the inclusive FEV1 evaluation, among them, in 5 re-
searches6-8,18,19 the mounting group plus Western Medi-
cine group was compared with the Western Medicine
group, and in 3 researches28-30 the mounting group was
compared with the Western Medicine group. Among
the mounting plus Western Medicine group was com-
pared with the Western Medicine group of including
FVC evaluation, there was heterogeneity (I2=94%, P＜
0.000 01);When the mounting plus Western Medicine
group compared with the Western Medicine group of
including FEV1evaluation, there was heterogeneity (I2=
83%, P=0.001), between the mounting group and the
Western Medicine there was heterogeneity (I2=55%, P=
0.11);for inclusive FEV1% evaluation, there was het-
erogeneity between the mounting group plus Western
Medicine group and the Western Medicine group (I2=
89%, P＜0.000 01) and there was a good homogenei-
ty as mounting plus Western Medicine plus Chinese
drug compared with the Western Medicine (I2=0%, P=
0.61);for the evaluation including FEV1/FVC there
was heterogeneity as the mounting plus Western Medi-
cine group compared with the Western Medicine
group (I2=89%, P＜0.000 01), there was a good homo-
geneity as the mounting plus Chinese drug group com-
pared with the Chinese drug group (I2=0% , P=0.50),
and the mounting plus Western Medicine plus Chinese
drug compared with the Western Medicine group (I2=
18%, P=0.27). However, there was no obvious clinical
heterogeneity, so random effect model was used for Me-
ta analysis. For those with no heterogeneity among
groups, fixed effect model was used for Meta analysis.
The results indicated that there was no statistically sig-
nificant difference in FVC between the mounting plus
Western Medicine group and the Western Medicine
group [MD=0.21, 95%CI (-0.15, 0.58), P=0.25] (Fig-
ure 3), and there was significant difference in FEV1 be-
tween the mounting plus Western Medicine group and
the Western Medicine group [MD=0.29, 95% CI
(0.06, 0.52), P=0.01], there was no significant differ-
ence between the mounting group and the Western
Medicine group [MD=0.03, 95%CI (-0.09, 0.15), P=
0.66] (Figure 5);and there were significant differences
as all the groups containing mounting compared with
all the groups un-containing mounting [MD=0.20,
95% CI (0.03, 0.37), P=0.02] (Figure 4). In FEV1%
there was significant difference between the mounting
plus Western Medicine group and the Western Medi-
cine group [MD=4.22, 95%CI (0.85, 7.59), P=0.01],
no significant difference between the mounting plus
Western Medicine plus Chinese drug group compared
with the Western Medicine group [MD=0.65, 95%CI
(-1.81, 3.11), P=0.60](Figure 5). In FEV1/FVC, there
was no significant difference between the mounting
plus Western Medicine group and the Western Medi-
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Inclusive
research
Xu XY 2005
Zhen CX
2005
Xu YL 2008
Wang HF
2009
Guan QH
2009
Shi KH 2009
ZhuXL2010
Kan J 2010
Liu B 2010
Deng L 2010
Xia LQ 2010
Pan JH 2011
TanGB2011
Bi RR 2011
Yang JZ2011
GongR2010
WangLD
2009
Wang YF
2010
Zhang Y
2004
MouXH
2009
Fan C 2011
Pu MZ 2010
Peng MS
2006
Song RC
2008
Chen P 2009
Wang HY
2010
Zheng F
2010
Wei YD
2011
Ma MM
2011
Liu W 2008
Random
allocation
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
random
number table
unclear
random
number table
unclear
unclear
unclear
Stratified block
random
unclear
random
number table
random
number table
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
Allocation
hiding program
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
Blind
method
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
double-
blind
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
unclear
Description of
un-follow-up and
dropping-off
un-description
un-description
un-description
un-description
un-description
un-description
description
un-description
un-description
un-description
un-description
un-description
un-description
un-description
un-description
un-description
description
un-description
un-description
un-description
un-description
un-description
un-description
un-description
un-description
un-description
description
un-description
un-description
un-description
Intention
analysis
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
－
Grade
of
quality
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
Adverse event
un-description
description
un-description
un-description
un-description
un-description
un-description
description
un-description
un-description
un-description
un-description
un-description
un-description
un-description
description
description
description
un-description
un-description
un-description
un-description
un-description
un-description
un-description
un-description
description
un-description
description
un-description
Table 2 Evaluation of methodological quality of inclusive researches
508
JTCM |www. journaltcm. com December 15, 2012 |volume 32 | Issue 4 |
Li FS et al. Point application on COPD in stationary phase and effects on pulmonary function
cine group [MD=2.59, 95%CI (0.05, 5.13), P=0.05],
there was a significant difference between the mount-
ing plus Chinese drug group and the Chinese drug
group [MD=5.29, 95%CI (2.52, 8.07), P=0.0002], no
significant difference between the mounting plus Chi-
nese drug plus Western Medicine group and the West-
ern Medicine group[MD=2.56, 95%CI (-1.46, 6.57),
P=0.21](Figure 6).
Analysis on publishing deviation
In this study, the total effective rate was used for funnel
Inclusive
research
Li SY 2009
Li GQ 2010
Random
allocation
unclear
unclear
Allocation
hiding
program
unclear
unclear
Blind
method
unclear
unclear
Description of
un-follow-up and
dropping-off
un-description
description
Intention
analysis
－
－
Grade
of
quality
B
B
Adverse event
un-description
un-description
Figure 2 Meta analysis of therapeutic effects of mounting therapy or adjuvant therapy on COPD
PT: plaster theropy;WM:Westen Medicine; TCM: Traditional Chinese Medicine; COPD: chronic obstructive pulmonary disease.
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Figure 3 Meta analysis on comparison of effects of mounting plusWestern Medicine andWestern Medicine on FVC
FVC: force vital capacity.
Figure 4 Meta analysis on effects of mounting therapy or adjuvant therapy on FEV1 in the patient of COPD
PT: plaster theropy; WM: Westen Medicine; TCM: traditional Chinese Medicine; FEV1: force expiratory vol; COPD: chronic obstruc-
tive pulmonary disease.
Figure 5 Meta analysis on effects of mounting therapy or adjuvant therapy on FEV1% in the patient of COPD
PT: plaster theropy; WM: Westen Medicine; TCM: Traditional Chinese Medicine; FEV1: force expiratory vol; COPD: chronic obstruc-
tive pulmonary disease.
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plot analysis, and an incomplete symmetric figure
could be found, indicating that publishing deviation
possibly occurs (Figure 7).
DISCUSSION
In this study, the inclusive 32 researches all were ran-
domized controlled trials, among them, 4 researches
mentioned use of random number table method, one
used stratified block random method, all the research-
es were unclear about allocation hiding program, only
one research mentioned use of double blind method,
and in all the researches use of intention analysis was
not mentioned, 6 researches mentioned occurrence of
adverse event in the patient after mounting therapy
without mention of allocation hiding program. While
Figure 6 Meta-analysis on effects of mounting therapy or adjuvant therapy on FEV1/FVC in the patient of COPD
PT: plaster theropy; WM:Westen Medicine; TCM: Traditional Chinese Medicine; FVC: force vital capacity; FEV1: force expiratory vol-
ume 1; COPD: chronic obstructive pulmonary disease.
Figure 7 Analysis on funnel plot of clinically therapeutic effects of mounting therapy or adjuvant therapy on COPD
PT: plaster theropy;WM:Westen Medicine; TCM: Traditional Chinese Medicine; COPD: chronic obstructive pulmonary disease.
0.02 0.1 1 10 50
OR
SE (log[OR])
PT+WM vs WM PT+TCM vs TCM PT vs WM PT+TCM+WM vs WM
0
0.2
0.4
0.6
0.8
1
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a study hold that non-allocation hiding program could
make the intervenient effect exaggerate 30%-41%,38 ad-
ditionally, blind method was less used , but application
of blind method can make the results objective and reli-
able, otherwise selection deviation, implement devia-
tion , measurement deviation, etc, would be produced.
Therefore, the research quality was not high, all being
grade B. This result possibly influences university in
clinical application to a certain extent.
The study held that TCM mounting therapy or adju-
vant therapy had active significance in increase of clini-
cal therapeutic effects on chronic obstructive pulmo-
nary disease in stationary phase, able to increase clini-
cal therapeutic effects, and different combinations of
mounting therapy with other therapies showed differ-
ent effects. The mounting plus Western Medicine
group in the therapeutic effect was better than the
Western Medicine group, the mounting group was bet-
ter than the Western Medicine group, the mounting
plus Chinese drug plus Western Medicine group was
better than the Western Medicine group, with no sig-
nificant difference between the mounting plus Chinese
drug group and the simple Chinese group. The thera-
peutic effects of all the combined mounting groups
were superior to those in the corresponding Western
Medicine groups, with no significant differences as
compared with the Chinese drug group. In a certain ex-
tent it is indicated that if TCM mounting therapy , as
an external therapy, is combined with oral drugs, corre-
sponding Western Medicine should be selected as possi-
bly, and secondarily corresponding Chinese drug are se-
lected for combined treatment. Based on the results in
this study it is inferred that mechanisms of TCM
mounting and Chinese drugs are similar, and TCM
mounting has mutual complement with Western Medi-
cine to a certain extent. In this study, there were signifi-
cant differences in therapeutic effects as all the treat-
ment groups with TCM mounting compared with the
corresponding Western Medicine groups, but with no
significant difference as the TCM mounting plus Chi-
nese drug group compared with the Chinese drug
group. These possibly are related with limited inclusive
cases and no-high study quality.
Differed from TCM clinically therapeutic effect in
which there is a relatively unified criterion in whole na-
tion, possibly due to different machines and operations
for determination of pulmonary functions, leading to
heterogeneity among some groups. There was heteroge-
neity between the mounting plus Western Medicine
group and the Western Medicine group in inclusive
FVC evaluation, and there were heterogeneities in
FEV1 between the mounting plus Western Medicine
group and the Western Medicine group, and between
mounting group and the Western Medicine group; in
FEV1/FVC evaluation, there was heterogeneity be-
tween the mounting plus Western Medicine group and
the Western Medicine group, but with no clinical het-
erogeneity, so random effect model was used for Me-
ta-analysis. It was found that the mounting plus West-
ern Medicine group in FVC was superior to the West-
ern Medicine group, but other groups were not ana-
lyzed due to a less cases; and the mounting plus West-
ern Medicine group in FEV1 was superior to the West-
ern Medicine group, with no significant difference be-
tween the mounting plus Chinese drug group and the
Chinese drug group, and between the mounting group
and the Western Medicine group; The mounting plus
Western Medicine group in FEV1% was superior to
the Western Medicine group. There were no significant
differences in FEV1/FVC between the mounting plus
Western Medicine group and the Western Medicine
group, and between the mounting plus Chinese drug
plus Western Medicine group and the Western Medi-
cine group, and there was a significant difference be-
tween the mounting plus Chinese drug group and the
Chinese drug group. It is indicated that TCM mount-
ing therapy can strengthen the improving effects of
Western Medicine on FVC and FEV1, FEV1% , but
can not increase the improving degree of Chinese drug
on FEV1. However, For FEV1/FVC, TCM mounting
could increase the clinical therapeutic effect in the Chi-
nese drug group and could not increase the clinical ef-
fect in the Western Medicine group. These results fur-
ther indicate that Chinese drug and Western Medicine
have different models of therapeutic effect models in
treatment of chronic obstructive pulmonary disease, so
how to fully use superiority of TCM mounting therapy
to make summation of superiorities of both Chinese
drug therapy and Western Medicine therapy is a topic
worthy to research in future. .
Different combinations of TCM mounting therapy,
oral Chinese drug and Western Medicine have differ-
ent reflections in improving clinical therapeutic effects
and pulmonary function of chronic obstructive pulmo-
nary disease. These results provided by this study only
provide a reference for clinical treatment.
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